Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zavicefta

- PMLiVE

Pfizer wins new European approval for Prevenar 13

Expands use of pneumococcal disease vaccine to cover people aged 18 to 49

- PMLiVE

EMA in firing line as transparency debate widens

Swedish regulator claims EU agency withheld information on drug withdrawn from sale in 2008

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

Croatia joins European medicines network

Follows country's membership of the European Union

- PMLiVE

EMA commits to disclosure of data from trials

Seeks feedback on clinical trial data access policy

UK launch for Pfizer’s long-acting contraceptive injection Sayana

Becomes first contraceptive of its kind to reach the UK market

- PMLiVE

US charity calls for release of diabetes drug data

American Diabetes Association demands review of incretin-based medicines linked to pancreatic cancer

- PMLiVE

EMA seeks comment on final biosimilar guidance

Outlines thinking on non-clinical and clinical development requirements

Synexus South Africa research sites join Pfizer trial network

CRO's sites become the first in Africa to meet the pharma company's standards

- PMLiVE

New formulations of Pralia and Enbrel head list of new drugs in Japan

Regulator backs medicines from Pfizer, Takeda, Daiichi Sankyo, Astellas, Zeria and otsuka

- PMLiVE

­Pfizer signs $635m deal with CytomX for cancer ADCs

Will use biotech's Probody technology to develop antibody-drug conjugates

- PMLiVE

EMA backs Pomalidomide Celgene in multiple myeloma

Further positive CHMP opinions for new medicines form Aegerion, Teva and more

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links